Divi's Laboratories: Scaling New Heights in the Global CDMO Landscape
As of Wednesday, April 29, 2026, Divi's Laboratories Limited (DIVISLAB) stands as a bellwether for the Indian pharmaceutical manufacturing prowess, particularly in the highly technical and globally crucial Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) segments. The company has navigated the shifting paradigms of global supply chain de-risking and the increasing complexity of pharmaceutical chemistry with remarkable resilience, positioning itself as a strategic partner to the world’s leading pharmaceutical innovators.
Company Snapshot
| Metric | Value |
|---|---|
| NSE Symbol | DIVISLAB |
| Sector / Industry | Pharmaceuticals / API & CDMO |
| Market Cap | ₹1,71,000 Cr |
| CMP | ₹6,481.00 |
| 52W Range | ₹5,636.50 – ₹7,071.50 |
| P/E (TTM) | 68.89 |
| P/B | 11.07 |
| Dividend Yield | 0.46% |
| Promoter Holding | 51.88% |
| Beta | 0.78 |
*Data as of Wednesday, April 29, 2026.